Opexa Therapeutics

2635 Technology Forest Blvd , The Woodlands, TX 77381

Public
Healthcare & Pharmaceuticals - Biotechnology
around $2.5 - 5M
around 20 - 50
(281) 775-0600
(281) 872-8585


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company?s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tovaxin is a T-cell immunotherapy positioned to enter Phase III clinical development for the treatment of relapsing remitting MS (RR-MS). In November 2011, the Company re-acquired the stem cell assets from Novartis Pharmaceuticals. Tovaxin is a personalized therapy that is specifically tailored to each patient?s disease profile. Tovaxin is manufa... (Source: SEC reports)


Competitor - 1/9
Which company is more competitive with Opexa Therapeutics?


6 Contacts at this company
Catherine deSombre
Director of Analytical Services ...
Kenny Frazier
Head of Global Prescription Development
Judy Kemper
Executive Administrator
Brian Newsom
Senior Director of R&D
Mary Riser
Director
Neil Warma
Founder and CEO

No company news available.
Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.